FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to the treatment of heart failure with preserved ejection fraction. The following is disclosed: the use of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl-2'-(pentanoyl{2''-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate]hemipentahydrate (LCZ696) to improve, stabilize, or slow the worsening of the NYHA classification in patients with heart failure with preserved ejection fraction (HFpEF).
EFFECT: use of the invention makes it possible to effectively improve, stabilize and/or slow down the deterioration of the condition of patients suffering from heart failure with preserved ejection fraction.
10 cl, 1 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | 2013 |
|
RU2667643C2 |
| PHARMACEUTICAL COMPOSITIONS INCLUDING VALSARTAN AND INHIBITORS OF NEUTRAL ENDOPEPTITAS (NEP) | 2003 |
|
RU2334513C2 |
| TREATMENT OF HYPERTENSION AND/OR PREVENTION AND TREATMENT OF HEART FAILURE IN MAMMAL, RECEIVING ANTICOAGULANT THERAPY | 2011 |
|
RU2564941C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
| METHOD OF PRODUCING INTERMEDIATE COMPOUNDS FOR PREPARING NEP INHIBITORS | 2011 |
|
RU2588572C2 |
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2017 |
|
RU2773029C2 |
| SUBSTITUTED DERIVATIVES OF BISPHENYL ESTER OF BUTYRIC ACID AS NEP INHIBITORS | 2019 |
|
RU2784522C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| NEW METHOD AND NEW INTERMEDIATE COMPOUNDS | 2016 |
|
RU2769445C2 |
